Table I

Autism/Tourette’s studies – Atypical Antipsychotics Compared to Conventional Antipsychotics

Adverse EventsDrug# of studiesConventionalsIntervention GroupsPooled OR95% CI
# adverse eventssample size# adverse eventssample size
Appetite or Weight/DecreaseOlanzapine116060.00(0.00, 39.00)
Appetite or Weight/IncreaseOlanzapine15666+Inf(0.03, Inf+ )
Appetite or Weight/IncreaseRisperidone1202422261.10(0.18, 6.75)
Cardiovascular/BP/DecreaseOlanzapine116060.00(0.00, 39.00)
DermatologicOlanzapine116060.00(0.00, 39.00)
GastrointestinalOlanzapine10626+Inf(0.19, Inf+ )
HEENT/Decreased SalivationOlanzapine116161.00(0.01, 94.01)
Neuro/FatigueRisperidone192410261.04(0.29, 3.81)
Neuro/HeadacheRisperidone12245262.57(0.37, 29.80)
Neuro/Movement DisorderRisperidone15242260.32(0.03, 2.25)
Neuro/Movement Disorder/EPSOlanzapine126060.00(0.00, 5.16)
Neuro/Movement Disorder/EPSRisperidone18244260.37(0.07, 1.68)
Neuro/Movement Disorder/GaitOlanzapine116060.00(0.00, 39.00)
Neuro/Movement Disorder/Tardive DyskinesiaOlanzapine10606NCNC
Neuro/SedationOlanzapine126567.96(0.43, 588.32)
Neuro/SedationRisperidone1102412261.20(0.34, 4.25)
Psychiatric/DepressionRisperidone16248261.33(0.33, 5.68)
Psychiatric/SleepOlanzapine10616+Inf(0.03, Inf+ )
Psychiatric/SleepRisperidone17241260.10(0.00, 0.90)
TraumaRisperidone16241260.12(0.00, 1.16)
UrinaryOlanzapine116161.00(0.01, 94.01)

NC = Not Calculated

From: Appendix E, Adverse Event Analysis

Cover of Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics
Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics [Internet].
Comparative Effectiveness Reviews, No. 6.
Shekelle P, Maglione M, Bagley S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.